1. Home
  2. GCMG vs TBPH Comparison

GCMG vs TBPH Comparison

Compare GCMG & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GCMG
  • TBPH
  • Stock Information
  • Founded
  • GCMG 1971
  • TBPH 2013
  • Country
  • GCMG United States
  • TBPH United States
  • Employees
  • GCMG N/A
  • TBPH N/A
  • Industry
  • GCMG Finance/Investors Services
  • TBPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • GCMG Finance
  • TBPH Health Care
  • Exchange
  • GCMG Nasdaq
  • TBPH Nasdaq
  • Market Cap
  • GCMG 631.4M
  • TBPH 699.0M
  • IPO Year
  • GCMG N/A
  • TBPH N/A
  • Fundamental
  • Price
  • GCMG $12.88
  • TBPH $14.05
  • Analyst Decision
  • GCMG Buy
  • TBPH Strong Buy
  • Analyst Count
  • GCMG 4
  • TBPH 4
  • Target Price
  • GCMG $15.13
  • TBPH $23.00
  • AVG Volume (30 Days)
  • GCMG 464.3K
  • TBPH 516.3K
  • Earning Date
  • GCMG 11-07-2025
  • TBPH 11-11-2025
  • Dividend Yield
  • GCMG 3.44%
  • TBPH N/A
  • EPS Growth
  • GCMG N/A
  • TBPH N/A
  • EPS
  • GCMG 0.19
  • TBPH 0.26
  • Revenue
  • GCMG $533,097,999.00
  • TBPH $77,205,000.00
  • Revenue This Year
  • GCMG $4.88
  • TBPH $79.82
  • Revenue Next Year
  • GCMG $11.78
  • TBPH N/A
  • P/E Ratio
  • GCMG $68.81
  • TBPH $54.21
  • Revenue Growth
  • GCMG 15.56
  • TBPH 24.49
  • 52 Week Low
  • GCMG $10.74
  • TBPH $7.88
  • 52 Week High
  • GCMG $14.48
  • TBPH $14.55
  • Technical
  • Relative Strength Index (RSI)
  • GCMG 56.30
  • TBPH 61.75
  • Support Level
  • GCMG $12.72
  • TBPH $13.86
  • Resistance Level
  • GCMG $13.01
  • TBPH $14.42
  • Average True Range (ATR)
  • GCMG 0.21
  • TBPH 0.43
  • MACD
  • GCMG -0.02
  • TBPH -0.07
  • Stochastic Oscillator
  • GCMG 65.52
  • TBPH 53.70

About GCMG GCM Grosvenor Inc.

GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: